BMJ: cerebral venous thrombosis about 20 times more common after AstraZeneca vaccine

Astrazeneca, Australia, Coronavirus, England, Europe, Health, Northern Ireland, Science, Scotland, Side Effects, UK, Vaccine, Wales

The risk of thrombosis at 11 excess events per 100 000 vaccinations  are higher than estimated by the European Medicines Agency. The EMA estimates the risk of thrombosis to be between 1 and 2 per 100 000 people, depending on age.  Among the venous thromboembolic events, the most notable was cerebral venous thrombosis, which was about 20 times more common after the Oxford-AstraZeneca vaccine than expected with an excess risk of 2.5 per 100 000 vaccinations. Venous thromboembolic events were more common in women than in men and were also more common in people aged 18-44 than in those aged 45-65. Thrombocytopenia and bleeding were mildly increased after vaccination, but not significantly. 

BMJ Opinion –  Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination

Study Paper here: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study



Europe: EMA assessing reports of Guillain-Barre syndrome with AstraZeneca’s coronavirus vaccine VaxZevria


Scotland: Severe reaction to Astrazeneca vaccine turned woman’s legs into ‘giant blisters’


UK: AstraZeneca coronavirus vaccine blood clot cases double to 168 in two weeks, 32 deaths reported


** This post was originally published on May 11, 2021 **